Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:EGRXNASDAQ:EPZMNASDAQ:KMDANASDAQ:THRN On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeEGRXEagle Pharmaceuticals$2.79-3.0%$2.02$1.50▼$2.88$36.23M0.839,285 shs2,812 shsEPZMEpizyme$1.47$1.47$0.41▼$5.80$247.44M-0.413.23 million shs7,960 shsKMDAKamada$7.26+0.8%$6.80$4.83▼$9.16$414.04M0.9494,678 shs75,623 shsTHRNThorne HealthTech$10.19$10.18$3.41▼$10.20$549.45M0.82110,986 shsN/AReduce the RiskMarket downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceEGRXEagle Pharmaceuticals0.00%+19.79%+43.75%+98.28%-30.56%EPZMEpizyme0.00%0.00%0.00%0.00%0.00%KMDAKamada0.00%+4.65%+8.60%+1.41%+50.63%THRNThorne HealthTech0.00%0.00%0.00%0.00%0.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationEGRXEagle PharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/AEPZMEpizymeN/AN/AN/AN/AN/AN/AN/AN/AKMDAKamada4.1366 of 5 stars3.43.00.00.02.91.73.8THRNThorne HealthTechN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceEGRXEagle Pharmaceuticals 0.00N/AN/AN/AEPZMEpizyme 0.00N/AN/AN/AKMDAKamada 2.75Moderate Buy$14.67102.02% UpsideTHRNThorne HealthTech 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest EPZM, THRN, KMDA, and EGRX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/15/2025KMDAKamadaBenchmarkSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$15.00 ➝ $15.005/8/2025KMDAKamadaSidotiSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeHold(Data available from 6/23/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookEGRXEagle Pharmaceuticals$257.55M0.14$6.98 per share0.40N/A∞EPZMEpizyme$37.43M6.61N/AN/A($0.54) per share-2.72KMDAKamada$160.95M2.59$0.50 per share14.65$4.51 per share1.61THRNThorne HealthTech$228.73M2.40$0.26 per share39.41$2.78 per share3.67Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateEGRXEagle Pharmaceuticals$35.64MN/A0.00∞N/AN/AN/AN/AN/AEPZMEpizyme-$251.12M-$1.72N/AN/AN/A-391.90%-2,459.33%-69.74%N/AKMDAKamada$14.46M$0.2925.0322.690.879.60%6.31%4.43%8/13/2025 (Estimated)THRNThorne HealthTech$15.67M$0.3826.8211.45N/A7.84%9.03%5.57%N/ALatest EPZM, THRN, KMDA, and EGRX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/14/2025Q1 2025KMDAKamada$0.07$0.07N/A$0.07$154.06 million$44.02 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthEGRXEagle PharmaceuticalsN/AN/AN/AN/AN/AEPZMEpizymeN/AN/AN/AN/AN/AKMDAKamadaN/AN/AN/AN/AN/ATHRNThorne HealthTechN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioEGRXEagle PharmaceuticalsN/AN/AN/AEPZMEpizymeN/A5.355.19KMDAKamadaN/A3.301.93THRNThorne HealthTech0.162.411.13Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipEGRXEagle Pharmaceuticals85.36%EPZMEpizyme76.45%KMDAKamada20.38%THRNThorne HealthTech9.48%Insider OwnershipCompanyInsider OwnershipEGRXEagle Pharmaceuticals28.90%EPZMEpizyme23.40%KMDAKamada36.10%THRNThorne HealthTech75.00%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableEGRXEagle Pharmaceuticals10012.99 million9.23 millionNo DataEPZMEpizyme250168.33 million128.97 millionOptionableKMDAKamada36057.51 million36.75 millionOptionableTHRNThorne HealthTech54453.92 million13.48 millionOptionableEPZM, THRN, KMDA, and EGRX HeadlinesRecent News About These CompaniesAuburn QB Payton Thorne gets Venmo requests from angry fans after brutal performancesSeptember 12, 2024 | nypost.comFive healthtech trends to watch in 2024July 21, 2024 | pharmaphorum.comDr. Gary A. ThorneFebruary 22, 2024 | health.usnews.comLisa D. ThorneFebruary 3, 2024 | health.usnews.comTHORNE HEALTHTECH ANNOUNCES INNOVATION ARM UNDER THORNE VENTURESDecember 22, 2023 | morningstar.comBella Thorne, OnlyFans and the battle over monetising contentDecember 8, 2023 | bbc.comBest Redhead OnlyFans Girls Bringing Fire on Only Fans in 2024November 21, 2023 | philadelphiaweekly.comDr. Doris K. ThorneNovember 17, 2023 | health.usnews.comL Catterton Completes Acquisition of Thorne HealthTech, Inc.October 16, 2023 | finance.yahoo.comL Catterton and Thorne HealthTech, Inc. Announce Expiration of Tender OfferOctober 13, 2023 | finance.yahoo.comEvercore ISI Group Downgrades Thorne Healthtech (THRN)October 11, 2023 | msn.comSHAREHOLDER NOTICE: Brodsky & Smith Announces an Investigation of Thorne HealthTech, Inc. (THRN)September 20, 2023 | markets.businessinsider.comShould You Be Adding Thorne HealthTech (NASDAQ:THRN) To Your Watchlist Today?September 19, 2023 | finance.yahoo.comSHAREHOLDER ALERT: The M&A Class Action Firm Continues Investigating the Merger – THRN,September 14, 2023 | bakersfield.comBRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Thorne HealthTech, Inc. (Nasdaq - THRNSeptember 7, 2023 | bloomberg.comTD Cowen Downgrades Thorne Healthtech (THRN)August 30, 2023 | msn.comTHORNE HEALTHTECH INVESTOR ALERT by the Former...August 30, 2023 | benzinga.comThorne HealthTech IncAugust 29, 2023 | jp.reuters.comShareholder Alert: Ademi LLP investigates whether Thorne HealthTech, Inc. has obtained a Fair Price in its transaction with L CattertonAugust 28, 2023 | benzinga.comThorne HealthTech Goes Private In $680M Cash Deal With L Catterton; Stock SoarsAugust 28, 2023 | msn.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeEPZM, THRN, KMDA, and EGRX Company DescriptionsEagle Pharmaceuticals NASDAQ:EGRX$2.79 -0.09 (-2.96%) As of 02:21 PM EasternEagle Pharmaceuticals, Inc., a pharmaceutical company, focuses on developing and commercializing product candidates to treat diseases of the central nervous system or metabolic critical care, and oncology in the United States. The company offers Ryanodex for malignant hyperthermia; and Belrapzo and Bendeka for chronic lymphocytic leukemia and indolent B-cell non-Hodgkin's lymphoma. Its product candidates also include EP-4104, a dantrolene sodium to treat organophosphate exposure; PEMFEXY, a ready-to-use/dilute liquid form of pemetrexed for non-small cell lung cancer and mesothelioma; EA-114 (fulvestrant) for HR+/HER- breast cancer; and Vasopressin injection, which is indicated to enhance blood pressure in adults with vasodilatory shock. The company has license and collaboration agreements with Combioxin, SA for the development and commercialization rights to CAL02, an antitoxin agent for the treatment of severe pneumonia in combination with traditional antibacterial drugs; and AOP Orphan Pharmaceuticals GmbH for the commercial rights of Landiolol, a novel therapeutic product candidate for the short-term reduction of ventricular rate in patients with supraventricular tachycardia, including atrial fibrillation and atrial flutter. It has a strategic collaboration with Tyme Technologies, Inc. for the development of SM-88 to treat breast cancer (HR+/HER2-) and high-risk metastatic sarcomas. Eagle Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Woodcliff Lake, New Jersey.Epizyme NASDAQ:EPZMEpizyme, Inc., a commercial-stage biopharmaceutical company, discovers, develops, and commercializes novel epigenetic medicines for patients with cancer and other diseases in the United States. The company offers Tazemetostat for the treatment of metastatic or locally advanced epithelioid sarcoma for adults and pediatric patients. It also develops R-CHOP in front-line patients with high risk diffuse large B-cell lymphoma; and PARP inhibitor in patients with PARPi-resistant solid tumors, such as castration-resistant prostate cancer, small cell lung cancer, and others. In addition, the company develops Tazemetostat in patients with INI1-negative tumors in adults and pediatrics; PRMT5 inhibitor for patients with solid tumors; and PRMT1 inhibitor. It has collaboration agreements with Roche Molecular Systems, Inc.; Lymphoma Academic Research Organization; Eisai Co. Ltd.; HUTCHMED (China) Limited; and Roche Sequencing Solutions, Inc. The company was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.Kamada NASDAQ:KMDA$7.26 +0.06 (+0.83%) Closing price 04:00 PM EasternExtended Trading$7.26 +0.00 (+0.07%) As of 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Kamada Ltd. manufactures and sells plasma-derived protein therapeutics. Its commercial products include KAMRAB/KEDRAB for treating prophylaxis of rabies; CYTOGAM for Prophylaxis of Cytomegalovirus disease in kidney, lung, liver, pancreas, heart, and heart/lung transplants; VARIZIG for post exposure prophylaxis of varicella; WINRHO SDF for immune thrombocytopenic purpura and suppression of rhesus isoimmunization; HEPAGAM B for prevention of hepatitis B recurrence liver transplants and post-exposure prophylaxis; GLASSIA for intravenous AATD; KAMRHO (D) IM for prophylaxis of hemolytic disease of newborns; KAMRHO (D) IV for immune thermobocytopunic purpura; and Echis coloratus and Vipera palaestinae Antiserum for the treatment of snake bite. The company also distributes imported drug products in Israel, including BRAMITOB to manage chronic pulmonary infection; FOSTER to treat asthma; TRIMBOW for chronic obstructive pulmonary disease; PROVOCHOLINE for the diagnosis of bronchial airway hyperactivity; AEROBIKA, an OPEP device; RUPAFIN and RUPAFIN ORAL SOLUTION for allergic rhinitis and Urticaria; SINTREDIUS for rheumatoid arthritis, systemic lupus erythematosus, and mild-moderate juvenile dermatomyositis; IVIG for immunodeficiency-related conditions; VARITECT for chicken pox and zoster herpes; ZUTECTRA and HEPATECT CP for hepatitis B; MEGALOTECT CP for CMV virus; RUCONEST for angioedema attack; HEPARIN SODIUM INJECTION for thrombo-embolic disorders and prophylaxis of deep vein thrombosis and thromboembolic events; ALBUMIN and ALBUMIN for blood plasma; Factor VIII for hemophilia type A; and Factor IX for hemophilia type B. In addition, it distributes COAGADEX for hereditary factor X deficiency; IXIARO for Japanese encephalitis; VIVOTIF for Salmonella Typhi; PROCYSBI for nephropathic cystinosis; LAMZEDE for alpha-mannosidosis; ELIGARD for prostate cancer; and BEVACIZUMAB KAMADA for various cancers. The company was incorporated in 1990 and is headquartered in Rehovot, Israel.Thorne HealthTech NASDAQ:THRNThorne HealthTech, Inc., a science-driven wellness company, provides solutions and personalized approaches to health and wellness in the United States and internationally. It offers various health tests, such as sleep, stress, weight management, gut health, heavy metals, biological age, and other health tests that generate molecular portraits for its customers, as well as develops nutritional supplements and offers wellness education solutions. The company uses the Onegevity platform to map, integrate, and understand the biological features that describe the state of an individual's health, as well as provide actionable insights and personalized data, products, and services that help individuals to take a proactive approach to enhance and maintain their health. It primarily serves healthcare professionals, professional athletes, and professional sports and Olympic teams. Thorne HealthTech, Inc. was founded in 1984 and is headquartered in New York, New York. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Microsoft Stock Holds Steady as AI Drives Workforce Shift Top International ETFs With Dividends and Market-Beating Returns D-Wave Goes International With South Korea Partnership BigBear.ai Poised to Benefit as Palantir Dominates AI Defense Kroger Stock Confirms Buy Signal as Uptrend Gains Strength Darden Stock Set to Sizzle After Blowout Q4 and $1B Buyback Alphabet’s Comeback: The Hidden Engines Powering Google New All-Time Highs Coming for Broadcom? Wall Street Says Yes Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
